Refractory Angina Clinical Trial
Official title:
Cardiac Rehabilitation in Patients With Refractory Angina
The purpose of this study is to evaluate the safety and feasibility of cardiovascular rehabilitation in Patients with refractory angina, evaluate the effect of cardiovascular rehabilitation in patients with angina Refractory, by maximal oxygen consumption (VO2max) and global myocardial ischemic load by Stress Echocardiography; To evaluate the presence of myocardial injury, caused by physical stress, through ultra-sensitive troponin after sessions of aerobic physical activity, evaluating the behavior during the training period; To evaluate the effect of rehabilitation on the modulation of sympathetic activity and inflammation, muscular blood flow and lipid metabolism; To evaluate of the effect of rehabilitation on ventricular function through Stress echocardiography; Detection of ischemic episodes and arrhythmias identified during the Rehabilitation sessions through external cardiac monitoring (telemetry); Evaluate the quality of life assessment through the SF-36 questionnaire, Canadian Cardiovascular Society, the number of symptomatic episodes of ischemia, daily sublingual nitrate intake.
After signing the informed consent form, patients will be randomized into 4 groups: 1. Optimized clinical treatment group + physical training for 12 weeks (TF); 2. optimized clinical treatment group (CT); 3. Group with coronary insufficiency without angina (CD); Group 4: normal healthy subjects All patients will be submitted to the following procedures in 2 moments * (times 0 and 3): -Routine laboratory tests including study of total cholesterol, LDL-cholesterol, -HDL-cholesterol, including study of the functionality of HDL-c, triglycerides, complete blood count, renal function, fasting glycemia, glycosylated hemoglobin (HbA1C); - Dosage of biomarkers of myocardial ischemia (ultra-sensitive troponin); - Dosage of inflammatory markers: Tumor necrosis factor (TNFn), interleukins 1 and 6 (IL-1 and IL-6), ultra-sensitive C-reactive protein (CRP); - Vascular endothelial growth factor (VEGF) dosage; - ergospirometric test in cycloergometer; - Echocardiogram with physical stress with evaluation of myocardial perfusion and function; - Evaluation of sympathetic activity through microneurography; - Evaluation of vascular reactivity through ultrasound of the brachial artery. - Evaluation of muscular blood flow through plethysmography; - Isometric exercise protocols; - Mental stress protocol - Quality of Life Questionnaire; - Diary of angina. After the initial examinations, the candidates of the TF group will be evaluated by cardiovascular rehabilitation team, for training prescription, which will be performed in a hospital environment, supervised by a qualified doctor. The rehabilitation may be interrupted in any patient, for safety measure, if the investigator deems it appropriate. All patients in both groups will receive clinical follow-up during the protocol, with monthly consultations during the 12-week protocol period (time 0 to 3), in which clinical evaluations of symptoms and quality of life of the patients will be performed . Any clinical intercurrence will be promptly annotated and evaluated according to the need of the moment. After this period, routine outpatient follow-up is scheduled at the outpatient clinic, and counseling for unsupervised physical training, according to the results of the study. All laboratory, clinical, imaging, and functional parameters will be evaluated before and at the end of the protocol. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01205893 -
Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA
|
Phase 2 | |
Suspended |
NCT04306237 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
|
Phase 2 | |
Recruiting |
NCT04892537 -
Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance
|
N/A | |
Completed |
NCT00694642 -
Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis
|
Phase 1/Phase 2 | |
Suspended |
NCT00820586 -
Intramyocardial Delivery of Autologous Bone Marrow
|
Phase 2 | |
Recruiting |
NCT04368819 -
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
|
Phase 2/Phase 3 | |
Recruiting |
NCT05711849 -
Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina
|
Phase 2 | |
Recruiting |
NCT03455725 -
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
|
N/A | |
Completed |
NCT01966042 -
Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina
|
Phase 2 | |
Recruiting |
NCT03991871 -
HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study
|
N/A | |
Recruiting |
NCT05102019 -
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
|
N/A | |
Completed |
NCT01796912 -
Lipoprotein Apheresis in Refractory Angina Study
|
N/A | |
Completed |
NCT03350737 -
Coronary Arteriogenetic Heparinized Exercise
|
N/A | |
Recruiting |
NCT01566175 -
Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization
|
N/A | |
Recruiting |
NCT05492110 -
Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.
|
N/A | |
Recruiting |
NCT04606459 -
COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina
|
N/A |